Clinical Research
Opportunities
Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate
Get Started
Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Featured studies
UPCC 31920 Penn Medicine BioBank
The Penn Medicine Biobank is collecting and storing biological specimens such as blood, as well as health information from volunteers. These samples and this information allow researchers to use them for research studies including but not limited to COVID-19, cancer, diabetes, and heart disease.
The GRoceries Aimed at Increasing Nutrition Study (GRAIN Study)
We are looking for adults ages 45-70 to take part in an 18-week study about people‘s online grocery shopping habits. You’ll get a free Walmart+ membership for your grocery deliveries and receive $10 back on all weekly orders over $35. You may earn over $200 in total for completing study …
Adult Virome Study
Did you know that all of us, including all healthy people, have viruses in our bodies that do not make us sick but actually may contribute to health? Researchers are exploring the viruses that exist in people that are not currently sick in order to understand their role in human …
Click & Pick Study
The University of Pennsylvania is conducting a 6-week research study to learn about your experience using online grocery stores and online restaurant ordering applications.
MethaLoad Dose-Finding Study
You may qualify for a paid research study that tests a new way of starting methadone for people using fentanyl. The standard approach to starting methadone uses low doses that increase slowly over time. This study tests whether a higher starting dose, called a loading dose, works better by reducing …
Recently Added/Updated trials
UPCC 18325 A Pilot Study of Ultra-High Dose Rate (ConformalFLASH), for Reirradiation of Carcinoma of the Head and Neck
This research study is being conducted to determine the feasibility of delivering FLASH ultra-high dose-rate proton-therapy (ConformalFLASH) to patients requiring reirradiation of their head and neck cancer.
UPCC 01226 Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
We would like to rely on WCG IRB as the IRB of Record for this study.
UPCC 07623 Effect of Immune Checkpoint Inhibitors on Coronary Microvasculature
This is an observational study that includes patients with breast cancer or non-small
cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The
investigators will use echocardiograms, blood draws, and PET stress tests to understand
how ICI therapy affects the heart and circulatory system.
UPCC 03922 A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety,
tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2
dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants
with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid
tumors.
The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat
in adult participants with metastatic or locally advanced MTAP-null solid tumors.
UPCC 51423 A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
The purpose of this study is to characterize safety and to determine the Recommended
Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose
Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort
Expansion). For U.S. sites: the purpose of this study is to characterize the safety and
to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and
part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s)
in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential
thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF
only.
Penn Medicine experts answer questions from patient advocates and share groundbreaking medical developments happening at the University of Pennsylvania.
Please choose between Voice or SMS based delivery of verification code
or